% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

panama53red 21 posts  |  Last Activity: 22 hours ago Member since: Jul 15, 2006
  • panama53red panama53red Apr 5, 2016 11:19 AM Flag

    He has bet on the wrong horse

    antisense is a true platform, dsRNAi is not a real platform as each drug needs to be developed on an individual basis almost like small molecules and there is no predictability on their safety profile. ALNY is worth maybe $30 a share at best. Their TTRx infusion drug is going to be a flop and the SC version KD is about the same as IONIS version with a worst safety profile. ALNY has nothing in its pipeline worth talking about.

45.45+0.06(+0.13%)Jun 30 4:00 PMEDT